{"id":"NCT03440814","sponsor":"Soleno Therapeutics, Inc.","briefTitle":"A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-05-09","primaryCompletion":"2020-05-01","completion":"2020-05-01","firstPosted":"2018-02-22","resultsPosted":"2023-09-21","lastUpdate":"2023-09-21"},"enrollment":127,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Prader-Willi Syndrome"],"interventions":[{"type":"DRUG","name":"DCCR","otherNames":[]},{"type":"DRUG","name":"Placebo for DCCR","otherNames":[]}],"arms":[{"label":"DCCR","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this is study is to evaluate the effects of DCCR (diazoxide choline controlled release tablets) in children and adults with Prader-Willi syndrome.","primaryOutcome":{"measure":"Hyperphagia Questionnaire (HQ-CT) Change From Baseline at Visit 7 (Week 13)","timeFrame":"Baseline to Visit 7 (Week 13)","effectByArm":[{"arm":"DCCR","deltaMin":-5.94,"sd":0.879},{"arm":"Placebo for DCCR","deltaMin":-4.27,"sd":1.145}],"pValues":[{"comp":"OG000 vs OG001","p":"0.1983"}]},"eligibility":{"minAge":"4 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":29,"countries":["United States","United Kingdom"]},"refs":{"pmids":["38671361","37919617","36639249"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":84},"commonTop":["Hypertrichosis","Oedema peripheral","Upper respiratory tract infection","Headache","Hyperglycaemia"]}}